Its somewhat pharmaceutical change, but looking for opportunities to fade the GLP-1 craze, which seems to be almost as extreme as the AI hype in both directions
The current market is largely private via patients who are self-paying, he said
10.1002/mnfr.201100217 116 SimonF.Leiva-SalcedoE.ArmisnR.RiverosA.CerdaO.VarelaD.et al
In his practice, patients who begin with lower doses of Ozempic or Mounjaro often report fewer side effects and greater comfort, which improves their ability to stay consistent with treatment
The Peptide Pathways Report analyzes 33 genetic insights in the weight management pathway covering these variants and more across 8 GLP-1 class and adjacent peptides
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised controlled trial